FT : BYD rejects EU claims subsidies help reduce price of China-made cars

BYD rejects EU claims subsidies help reduce price of China-made cars
Chinese auto group’s European head says success is due to BYD’s unique technology and management efficiency

BYD has rejected EU accusations that the success of Chinese car companies stemmed from state aid as Brussels forges ahead with a probe into whether local subsidies were helping electric cars made in China undercut European-made models.

“Our success is not because of the subsidy, it’s because we have unique technology . . . and our management efficiency is high,” said Michael Shu, European president of BYD, one of China’s leading auto groups.

“It’s because we invested in this technology much earlier, and much more, than competitors. It’s not because of the subsidy,” he added in the company’s first public comment on the probe launched last year.

The European Commission’s investigation into Chinese competitiveness in the electric vehicle market is widely expected to lead to higher tariffs. China’s ambassador to Europe previously called the move “unfair”.

The manufacturing subsidies the carmaker receives from China are “very limited”, Shu told the Financial Times in an interview at the Geneva Motor Show.

Carmakers such as Renault and Stellantis have warned that a wave of cheaper Chinese models will undercut those produced by European companies. But Shu said of the established industry: “They are afraid they cannot offer a competitive price.”

BYD, which is backed by Warren Buffett, has launched three models across Europe and is expanding its line-up and sales countries. Shu previously said the company aimed to be one of the top EV sellers in the region by 2030.

He said the company’s cost was “getting lower” as it produced more cars. The business has also launched its own ship to transport vehicles from China to Europe, which further reduces costs, he added.

Although any increase in tariffs may affect the speed of its rollout, “we are making some preparations . . . we will try our best to stabilise the sales price of the products in the market”, he said. Keeping prices stable “is quite important for long term relationship with customers, and brand image”.

Higher tariffs may in fact lead the carmaker to increase the planned capacity of the new EV factory it is building in Hungary, to reduce the number of imported cars, he added.

BYD expects to begin producing cars from the plant before the end of next year, despite having only announced the project in December, an incredibly rapid pace for an industry where factories can take four or more years to complete.

Shu said the Hungary plant planned to produce at least 150,000 cars a year, a minimum level for standard car factories. “We are still discussing how fast we can go and how many cars we can sell”, but it has to be at least 150,000 “otherwise the cost will be too high”.

BYD has not disclosed investment figures yet because it is still in negotiations with the EU over financial support for the project, he said.

The group already runs a battery factory in the country, and chose the site of the factory in Szeged because it is close to the university that the company sees as a potential recruiting ground.

The company has also launched its own car-carrying vessel to ship vehicles from China, an industry first. The move reduces its emissions by using greener fuel and cuts the company’s transportation costs compared with outsourcing its shipments to other companies, Shu said.

“Shipping capacity is an important bottleneck,” he said, adding the new vessel could sail at “BYD’s planning” rather than leaving cars in port waiting for a ship, which was expensive.

>>> US Research Calls V2

Research Calls II
  • Upgrades:
    • Gap (GPS) upgraded to Neutral from Underweight at JP Morgan; tgt raised to $20
    • HashiCorp (HCP) upgraded to Overweight from Equal-Weight at Morgan Stanley; tgt raised to $30
    • Lifeway Foods (LWAY) upgraded to Outperform from Market Perform at Noble Capital Markets; tgt $14
    • MediaAlpha (MAX) upgraded to Outperform from Market Perform at BMO Capital Markets; tgt raised to $28
    • Meritage (MTH) upgraded to Outperform from Neutral at Zelman
    • National Health (NHI) upgraded to Outperform from Neutral at Wedbush; tgt raised to $64
    • National Health (NHI) upgraded to Overweight from Equal Weight at Wells Fargo; tgt raised to $63
    • Omega Health (OHI) upgraded to Overweight from Equal Weight at Wells Fargo; tgt raised to $35
    • Power Integrations (POWI) upgraded to Market Perform from Under Perform at Northland Capital; tgt $67
    • Root, Inc. (ROOT) upgraded to Outperform from Mkt Perform at Keefe Bruyette; tgt raised to $22
    • SJW (SJW) upgraded to Buy from Neutral at Seaport Research Partners; tgt $68
    • Southwestern Energy (SWN) upgraded to Neutral from Underperform at Mizuho; tgt raised to $9
    • Sun Country Airlines (SNCY) upgraded to Overweight from Equal-Weight at Morgan Stanley; tgt $21
    • Weave Communications (WEAV) upgraded to Strong Buy from Outperform at Raymond James; tgt $15
  • Downgrades:
    • Air Products (APD) downgraded to Hold from Buy at Argus
    • Barrick (GOLD) downgraded to Hold from Buy at Argus
    • Int'l Paper (IP) downgraded to Hold from Buy at Argus
    • Moderna (MRNA) downgraded to Reduce from Hold at HSBC Securities; tgt raised to $86
    • MYR Group (MYRG) downgraded to Neutral from Buy at Sidoti; tgt $165
    • Newmont Goldcorp (NEM) downgraded to Hold from Buy at Argus
    • Nordson (NDSN) downgraded to Sector Weight from Overweight at KeyBanc Capital Markets
    • Rivian Automotive (RIVN) downgraded to Hold from Buy at Truist; tgt lowered to $11
    • UDR (UDR) downgraded to Equal-Weight from Overweight at Morgan Stanley; tgt $37
    • Ventas (VTR) downgraded to Equal Weight from Overweight at Wells Fargo; tgt lowered to $46
  • Others:
    • CVS Health (CVS) initiated with an Outperform at Leerink Partners; tgt $88
    • Dentsply Sirona (XRAY) initiated with an Outperform at Leerink Partners; tgt $42
    • Envista (NVST) initiated with an Underperform at Leerink Partners; tgt $19
    • Excelerate Energy (EE) initiated with an Outperform at Northland Capital; tgt $23
    • GoodRx (GDRX) initiated with an Outperform at Leerink Partners; tgt $8
    • Henry Schein (HSIC) initiated with a Market Perform at Leerink Partners; tgt $78
    • Hims & Hers Health (HIMS) initiated with a Market Perform at Leerink Partners; tgt $10
    • IQVIA (IQV) initiated with an Outperform at Leerink Partners; tgt $290
    • Laboratory Corp (LH) initiated with an Outperform at Leerink Partners; tgt $260
    • McKesson (MCK) initiated with an Outperform at Leerink Partners; tgt $600
    • Monday.com (MNDY) initiated with a Buy at BofA Securities; tgt $280
    • Owens & Minor (OMI) initiated with a Market Perform at Leerink Partners; tgt $24
    • Patterson Companies (PDCO) initiated with an Outperform at Leerink Partners; tgt $36
    • Phreesia (PHR) initiated with a Buy at Truist; tgt $35
    • Premier (PINC) initiated with a Market Perform at Leerink Partners; tgt $22.50
    • Privia Health (PRVA) resumed with a Buy at Jefferies; tgt lowered to $25
    • Progyny (PGNY) initiated with an Outperform at Leerink Partners; tgt $49
    • R1 RCM (RCM) initiated with an Outperform at Leerink Partners; tgt $14
    • Sable Offshore Corp. (SOC) initiated with an Outperform at TD Cowen; tgt $20
    • Smartsheet (SMAR) initiated with an Underperform at BofA Securities; tgt $45
    • Teladoc (TDOC) initiated with a Market Perform at Leerink Partners; tgt $17
    • The Oncology Institute (TOI) resumed with a Buy at Jefferies; tgt $2.50
    • Walgreens Boots Alliance (WBA) initiated with a Market Perform at Leerink Partners; tgt $23

>>> Research Calls

Research Calls
  • Upgrades:
    • AvalonBay (AVB) upgraded to Overweight from Equal-Weight at Morgan Stanley; tgt raised to $191.50
    • Bentley Systems (BSY) upgraded to Buy from Neutral at Rosenblatt; tgt raised to $60
    • Celanese (CE) upgraded to Overweight from Neutral at Piper Sandler; tgt raised to $170
    • Fannie Mae (FNMA) upgraded to Outperform from Mkt Perform at Keefe Bruyette; tgt raised to $2
    • Fluence (FLNC) upgraded to Positive from Neutral at Susquehanna; tgt $24
    • Freddie Mac (FMCC) upgraded to Outperform from Mkt Perform at Keefe Bruyette; tgt raised to $2.50
  • Downgrades:
    • Agilon Health (AGL) downgraded to Market Perform from Outperform at TD Cowen; tgt lowered to $6.50
    • Agilon Health (AGL) downgraded to Hold from Buy at Jefferies; tgt lowered to $6.50
    • CareMax (CMX) downgraded to Hold from Buy at Jefferies; tgt raised to $7.50
    • Cogent Biosciences (COGT) downgraded to Neutral from Outperform at Robert W. Baird; tgt lowered to $8
    • Deutsche Lufthansa AG (DLAKY) downgraded to Equal Weight from Overweight at Barclays
    • FEMSA (FMX) downgraded to Neutral from Buy at BofA Securities
    • FTAI Aviation Ltd. (FTAI) downgraded to Hold from Buy at Stifel; tgt raised to $59
  • Others:
    • Accolade (ACCD) initiated with an Outperform at Leerink Partners; tgt $16
    • Align Tech (ALGN) initiated with a Market Perform at Leerink Partners; tgt $310
    • American Eagle (AEO) added to JP Morgan's Positive Catalyst Watch List
    • Amer Sports (AS) initiated with a Buy at Deutsche Bank; tgt $20
    • Amer Sports (AS) initiated with an Equal-Weight at Morgan Stanley; tgt $16
    • Amer Sports (AS) initiated with a Hold at HSBC Securities; tgt $16
    • Amer Sports (AS) initiated with an Overweight at Wells Fargo; tgt $19
    • Amer Sports (AS) initiated with a Buy at UBS; tgt $23
    • Amer Sports (AS) initiated with a Buy at Goldman; tgt $21
    • Amer Sports (AS) initiated with an Outperform at Evercore ISI; tgt $21
    • Amer Sports (AS) initiated with an Outperform at Robert W. Baird; tgt $20
    • Amer Sports (AS) initiated with an Overweight at JP Morgan; tgt $19
    • Amer Sports (AS) initiated with a Buy at Citigroup; tgt $19
    • Amer Sports (AS) initiated with a Buy at BofA Securities; tgt $18
    • Amer Sports (AS) initiated with a Outperform at Bernstein; tgt $18.50
    • Asana (ASAN) initiated with a Buy at BofA Securities; tgt $25
    • Astrana Health (ASTH, formerly Apollo Medical (AMEH) initiated with a Buy at Jefferies; tgt $50
    • Cardinal Health (CAH) initiated with an Outperform at Leerink Partners; tgt $125
    • Cencora (COR, formerly AmerisourceBergen (ABC) initiated with an Outperform at Leerink Partners; tgt $261
    • Certara (CERT) initiated with a Market Perform at Leerink Partners; tgt $19
    • Doximity (DOCS) initiated with a Market Perform at Leerink Partners; tgt $32
    • Drilling Tools International (DTI) initiated with a Hold at Jefferies; tgt $3
    • HF Sinclair (DINO) resumed with an Equal Weight at Barclays; tgt $60
    • Leonardo DRS (DRS) initiated with a Neutral at JP Morgan; tgt $23
    • Quest Diagnostics (DGX) initiated with a Market Perform at Leerink Partners; tgt $135

>>> Europe : Brokers Upgrades & Downgrades - 26th of February 2024 V3(++)

>>> Up
* Axa Raised to Outperform at Mediobanca SpA; PT 40 euros
* BASF Raised to Buy at Stifel; PT 59 euros
* BMW Raised to Buy at Bankhaus Metzler (+)
* Colruyt Raised to Outperform at BNPP Exane (+)
* Fannie Mae Raised to Outperform at KBW; PT $2
* Freddie Mac Raised to Outperform at KBW; PT $2.50
* FRoSTA Raised to Buy at GSC Research; PT 80 euros (+)
* Hybrid Software Group Raised to Buy at KBC Securities (+)
* LISI Raised to Add at Gilbert Dupont; PT 25 euros (+)
* NYAB Oyj Raised to Reduce at Inderes; PT 45 euro cents
* Sogefi Raised to Buy at Intesa Sanpaolo; PT 4 euros
* Southwestern Energy Raised to Neutral at Mizuho Securities

>>> Down
* Asos Cut to Hold at SocGen; PT 406 pence
* Halma Cut to Hold at HSBC; PT 2,500 pence
* Imerys Cut to Neutral at BNPP Exane; PT 31 euros (+)
* Lufthansa Cut to Equal-Weight at Barclays; PT 8.50 euros
* Lundbergforetagen Cut to Sell at DNB Markets; PT 485 kronor
* Moderna Cut to Reduce at HSBC; PT $86
* MPC Container Ships ASA Cut to Hold at Arctic Securities
* Nestle Cut to Hold at Stifel; PT 106 Swiss francs
* Norrhydro Group Cut to Reduce at Inderes; PT 1.80 euros
* Orion Cut to Underperform at Jefferies; PT 28 euros
* Rivian Cut to Hold at Truist Secs; PT $11
* Swiss Life Cut to Hold at Vontobel as Valuation Deemed Too High
* Ypsomed Cut to Hold at Octavian; PT 340 Swiss francs (+)

>>> Initiation
* Amer Sports Rated New Equal-Weight at Morgan Stanley; PT $16
* Cie des Alpes Reinstated Corporate at Edison Investment Research
* De Nora Rated New Buy at Jefferies; PT 20 euros
* Leonardo DRS Rated New Neutral at JPMorgan; PT $23
* NIBE Industrier Rated New Buy at Citi; PT 71 kronor
* PowerCell Rated New Buy at Pareto Securities; PT 53 kronor
* Tesla Rated New Hold at China Renaissance; PT $180.16
* Torm Reinstated Buy at Nordea; PT 270 kroner

>>> Call
* Barclays Sees Europe Flag Carriers Strong in 2024; Lufthansa Cut (+)
* Goldman Strategists Say Bullish Sentiment Has Scope to Broaden
* Holcim on Positive Catalyst Watch at JPM, Citing Likely Buyback (+)
* JPMorgan Strategists Say Profit Margins Appear to Be Peaking (+)
* Nestle Cut at Stifel on Waning Performance, Lack of Improvement
* NIBE Gets Buy Rating at Citi on Mid-Term Outlook; 2H Seen Solid (+)

>>> US Gapping down

Gapping down
In reaction to earnings/guidance
:
  • SSL -4%, ELAN -2.9%, PLTK -2.8%, FIS -2.5%, FDP -1.3%, BGNE -1.1%
Other news:
  • LUNR -26.1% (spacecraft tipped over after touching down on surface of the moon)
  • SHG -3.6% (board of directors of Shinhan Card, our wholly-owned credit card subsidiary, resolved to enter into the contract on the sale of long-term car rental business assets)
  • AA -3.2% (announces agreement with Alumina Limited on terms and process to acquire Alumina Limited in all-stock transaction)
  • ALLK -2.2% (presents preclinical data highlighting inhibition of MRGPRX2-mediated mast cell activation with AK006 at AAAAI 2024)
  • TCRX -2.1% (Presents Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR)
  • TPG -1.9% (announced that certain stockholders intend to offer 15,526,915 shares of TPG's Class A common stock)
  • STLA -1.1% (Stellantis and Ayvens reach frame agreement to buy up to 500,000 vehicles)
  • PLUG -1% (Plug Power and B. Riley entered into Amendment No. 1 to the Original Agreement of At Market Issuance Sales Agreement) .
Analyst comments:
  • AGL -4% (downgraded to Market Perform from Outperform at TD Cowen)
  • COGT -4% (downgraded to Neutral from Outperform at Robert W. Baird)
  • FMX -1.4% (downgraded to Neutral from Buy at BofA Securities)

>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:
  • FRPT +12.1%, LI +8.9%, DPZ +7.7%, BCRX +6.3%, PPC +5.6%, BRK.B +2.2%, KOS +1.5%
Other news:
  • ALVO +11.4% (Alvotech and Teva (TEVA) announce U.S. approval of SIMLANDI (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira; accepts offer for the sale of shares for a value of ~$166 million at a purchase price of $16.41 (ISK 2,250) per share)
  • TEVA +5.1% (Alvotech and Teva (TEVA) announce U.S. approval of SIMLANDI (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira)
  • CLDX +3.5% (Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria)
  • KALV +3.3% (Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting)
  • LZM +1.1% (announces two-phased development plan for the kabanga nickel project in Tanzania)
  • NVDA +1% (Positive Barrons article)
  • AVGO +0.9% (KKR (KKR) nearing deal to purchase software unit from Broadcom)
Analyst comments:
  • FLNC +5.6% (upgraded to Positive from Neutral at Susquehanna)
  • CE +1.8% (upgraded to Overweight from Neutral at Piper Sandler)